Date:
In this phase 2 trial involving adults with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis.
The New England Journal of Medicine: Search Results in Gastroenterology
Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.
© 2021 tagDiv. All Rights Reserved. Made with Newspaper Theme.
